Holen Sie sich die Stockscreener-App
17.59
1.46%
-0.26
Vorhandelsmarkt:
17.55
-0.04
-0.23%
Schlusskurs vom Vortag:
$17.85
Offen:
$17.95
24-Stunden-Volumen:
748.37K
Relative Volume:
0.54
Marktkapitalisierung:
$1.73B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.84M
KGV:
-37.43
EPS:
-0.47
Netto-Cashflow:
$-44.23M
1W Leistung:
+0.17%
1M Leistung:
+11.33%
6M Leistung:
+29.82%
1J Leistung:
+63.63%
1-Tages-Spanne:
$17.52
$18.00
1-Wochen-Bereich:
$17.52
$18.61
52-Wochen-Spanne:
$8.9055
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Vergleichen Sie SPRY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
17.59 | 1.72B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
Is ARS Pharmaceuticals Inc. a good long term investmentFree Market Dynamics Reports - jammulinksnews.com
ARS Pharmaceuticals Inc. Stock Analysis and ForecastHigh-octane gains - jammulinksnews.com
What analysts say about ARS Pharmaceuticals Inc. stockDynamic growth stocks - Autocar Professional
What drives ARS Pharmaceuticals Inc. stock priceHigh-velocity gains - jammulinksnews.com
MHRA approves needle-free adrenaline nasal spray for anaphylaxis - Yahoo Finance
EURneffy® (adrenaline nasal spray) Approved in the U.K. as - GlobeNewswire
Revolutionary Needle-Free Alternative to EpiPen Approved in UK: EURneffy Changes Anaphylaxis Treatment - Stock Titan
ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High? - Yahoo Finance
What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing' - Yahoo Finance
ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine (SPRY) - Seeking Alpha
(SPRY) Technical Data - news.stocktradersdaily.com
ARS Pharmaceuticals: 'Betting On The Come' (NASDAQ:SPRY) - Seeking Alpha
ARS Pharmaceuticals: Insider Liquidity vs. Institutional Buying – A Contrarian Opportunity? - AInvest
ARS Pharmaceuticals: Navigating Insider Sales Amid Growth Catalysts - AInvest
Raymond James reiterates strong buy on ARS Pharmaceuticals stock - Investing.com
ARS Pharmaceuticals (SPRY) Soars 4.48% on Earnings, Partnership - AInvest
ARS Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
High Growth Tech Stocks in US for June 2025 - simplywall.st
Ars pharma CCO Karas sells $240k in SPRY stock - Investing.com
Learn to Evaluate (SPRY) using the Charts - news.stocktradersdaily.com
ARS Pharmaceuticals | 6/18/25 - ktnv.com
FDA Reviewing Oral Epinephrine Film for Possible Approval - Allergic Living
Asthma Market to Expand Significantly by 2034, States - openPR.com
Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech - Barchart.com
ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN
Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier” - Insider Monkey
Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey
ARS Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily
Long Term Trading Analysis for (SPRY) - news.stocktradersdaily.com
Bank of America Corp DE Has $1.70 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals - WBFF
Ameriprise Financial Inc. Buys 36,928 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
BNP Paribas Financial Markets Purchases New Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ProShare Advisors LLC Buys 3,436 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $354,000 Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
Deutsche Bank AG Increases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
Neffy provides needle-free relief to those with allergic reactions - KOIN.com
ARS brings relief to your whole home - KOIN.com
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):